Evidence map›Paper›PMID 26979938›Full record

ArticleScientific reports2016

C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.

Amanda Atanasio, Vilma Decman, Derek White, Meg Ramos, Burcin Ikiz, Hoi-Ching Lee, Chia-Jen Siao, Susannah Brydges, Elizabeth LaRosa, Yu Bai and 17 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 4 pooled it
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 4 syntheses or guidelines pooled it, 262 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Intrathecal (GActa neuropathologica communications · 2026
    Article
  13. Review
  14. Intrathecal (GbioRxiv : the preprint server for biology · 2026
    Article
  15. Brain communications · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 1 institution in 1 country.

Amanda AtanasioRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Vilma DecmanRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Derek WhiteRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Meg RamosRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Burcin IkizRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Hoi-Ching LeeRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Chia-Jen SiaoRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Susannah BrydgesRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Elizabeth LaRosaRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Yu BaiRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Wen FuryRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Patricia BurfeindRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Ralica ZamfirovaRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Gregg WarshawRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Jamie OrengoRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Adelekan OyejideRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Michael FralishRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Wojtek AuerbachRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
William PoueymirouRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Jan FreudenbergRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Guochun GongRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Brian ZambrowiczRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
David ValenzuelaRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
George YancopoulosRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Andrew MurphyRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Gavin ThurstonRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Ka-Man Venus LaiRegeneron Pharmaceuticals, Inc, Tarrytown, NY USA.
Regeneron (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expansion of a hexanucleotide (GGGGCC) repeat in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Both the function of C9ORF72 and the mechanism by which the repeat expansion drives neuropathology are unknown. To examine whether C9ORF72 haploinsufficiency induces neurological disease, we created a C9orf72-deficient mouse line. Null mice developed a robust immune phenotype characterized by myeloid expansion, T cell activation, and increased plasma cells. Mice also presented with elevated autoantibodies and evidence of immune-mediated glomerulonephropathy. Collectively, our data suggest that C9orf72 regulates immune homeostasis and an autoimmune response reminiscent of systemic lupus erythematosus (SLE) occurs in its absence. We further imply that haploinsufficiency is unlikely to be the causative factor in C9ALS/FTD pathology.

Indexed as

AutoimmunityAnimalsAutoantibodiesC9orf72 ProteinCytokinesFemaleGlomerulonephritis, MembranoproliferativeGuanine Nucleotide Exchange FactorsLupus Erythematosus, SystemicLymphocyte ActivationLymphoid TissueMacrophagesMaleMice, 129 StrainMice, Inbred C57BLMice, KnockoutAutoantibodiesC9orf72 ProteinC9orf72 protein, mouseCytokinesGuanine Nucleotide Exchange Factors

Identifiers

PMID26979938
PMCPMC4793236
OpenAlexW2297261057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.